Traitement en cours

Veuillez attendre...

PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le mardi 27.07.2021 à 12:00 PM CEST
Paramétrages

Paramétrages

Aller à Demande

1. WO2003024990 - VARIANTS DU RECEPTEUR D'HORMONE DE LIBERATION DE LA CORTICOTROPINE DE TYPE 1, ET UTILISATIONS CORRESPONDANTES

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

WHAT IS CLAIMED IS:

1. DNA encoding a corticotropin releasing hormone receptor type 1 protein comprising an amino acid sequence selected from the group consisting of SEQ LD No. 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 31, 32, 33, 34, 35, 36, . and 37. .

2. A vector capable of expressing the DNA of claim 1 , wherein said vector comprises said DNA and regulatory elements necessary for expression of said DNA in a cell.

3. The vector of claim 2, wherein said DNA encodes a corticotropin releasing hormone receptor type 1 protein comprising an amino acid sequence selected from the group consisting of SEQ ID No. 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 31, 32, 33 , 34, 35, 36, and 37.

4. A host cell transfected with the vector of claim 2, wherein said vector expresses a corticotropin releasing hormone receptor type 1 protein.

5. The host cell of claim 4, wherein said cell is selected from the group consisting of bacterial cells, mammalian cells, plant cells and insect cells.

6. The host cell of claim 5, wherein said bacterial cell is E. coli.

7. An isolated corticotropin releasing hormone receptor type 1 protein encoded by the DNA of claim 1 and comprising an amino acid sequence selected from the group consisting of SEQ ID No. 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 31, 32, 33 , 34, 35, 36, and 37.

8. An antibody directed against the corticotropin releasing receptor type 1 protein of claim 7.

9. The antibody of claim 8, wherein said antibody is a monoclonal antibody.

10. A pharmaceutical composition comprising the corticotropin releasing hormone receptor type 1 protein of claim 7 and a pharmaceutically acceptable carrier.

11. A method of treating a pathophysiological state, comprising the step of administering the pharmaceutical composition of claim 10 to an individual in need of such treatment.

12. The method of claim 11, wherein said pathophysiological state is selected from the group consisting of hyperproliferative epidermal disorder, allergic contact dermatitis, autoimmune disorder, epidermal carcinogenesis, and malignant transformation of epidermal or dermal melanocytes.

13. The DNA of claim 1, wherein said sequence differs in codon sequence due to the degeneracy of the genetic code, and wherein said sequence encodes a corticotropin releasing hormone receptor type 1 protein.

14. A vector capable of expressing the DNA of claim 13, wherein said vector comprises said DNA and regulatory elements necessary for expression of said DNA in a cell.

15. A host cell transfected with the vector of claim 14, wherein said vector expresses a corticotropin releasing hormone receptor type 1 protein.

16. The host cell of claim 15, wherein said cell is selected from the group consisting of bacterial cells, mammalian cells, plant cells and insect cells.

17. The host cell of claim 15, wherein said bacterial cell is E. coli.

18. A method of protecting skin cells against damage induced by an environmental factor, comprising the step of:
inducing the expression of corticotropin releasing hormone receptor type lg in said skin cells, wherein th e expression of said receptor type lg protects said skin cells against said damage.

19. The method of claim 18, wherein said damage is induced by solar radiation.

20. The method of claim 18, wherein inducing the expression of corticotropin releasing hormone receptor type lg in said skin cells inhibits proliferation in said cells.

21. The method of claim 18, wherein inducing the expression of corticotropin releasing hormone receptor type lg in said skin cells regulates production of cAMP in said skin cells.

22. A method of screening for a compound that induces the expression of corticotropin releasing hormone receptor type If or lg, comprising the steps of:
contacting said compound with skin cells; and
determining the expression of said receptor type If o r lg in cells that are or are not treated with said compound, wherein increased expression of said receptor type If or lg in treated cells compared to untreated cells indicates said compound induces expression of said receptor type If or lg.

23. The method of claim 22, wherein said compound comprises a treatment for a pathophysiological state.

24. The method of claim 23, wherein said pathophysiological state is selected from the group consisting of hyperproliferative epidermal disorder and neuroendocrine disorder.

25. A method of regulating an extracellular concentration of corticotropin releasing hormone or corticotropin releasing hormone related peptides, comprising the step of:
administering corticotropin releasing hormone receptor type le or lh to an individual, wherein said receptor type le or lh regulates said extracellular concentration of corticotropin releasing hormone or corticotropin releasing hormone related peptides by binding and slowly releasing said hormone or said peptides in said individual.

26. The method of claim 25, wherein administering said receptor type le or lh comprises a treatment for a pathophysiological state.

27. The method of claim 25, wherein said pathophysiological state comprises an inflammatory skin disease.

28. The method of claim 27, wherein said skin disease is selected from the group consisting, of psoriasis, allergic contact dermatitis, and abnormal hair growth.

29. The method of claim 25, wherein administering said receptor type le or lh to the individual comprises injecting said receptor type le or lh intravenously.

30. The method of claim 25, wherein administering said receptor type le or lh to the individual inhibits production of cAMP in said individual.

31. The method of claim 25, wherein said receptor type le or lh comprises a complex between said receptor type 1 e or lh and said corticotropin releasing hormone or said corticotropin releasing hormone related peptides.

32. The method of claim 31, wherein said complex is administered to said individual by intravenous or intratissue injection.